AI-Generated Summary: In this personal account, infectious diseases pharmacist Dr. Maira Baseer shares her journey from hospital pharmacy operations to clinical practice and antimicrobial stewardship in Pakistan. Through real-world experiences with antibiotic optimization, interdisciplinary collaboration, and stewardship program development, she highlights how pharmacists can expand their impact from individual prescriptions to improving patient care across an entire hospital.

A journey from hospital pharmacy operations to infectious diseases and antimicrobial stewardship

Authored By Maira Baseer, Pharm.D.
Article Posted 16 November 2026
I am an infectious diseases (ID) pharmacist and antimicrobial stewardship (AMS) secretary working in a tertiary care hospital in Pakistan. My work brings me into close collaboration with physicians, microbiology teams, nurses, and other healthcare professionals caring for patients with complex infections, particularly in critical care settings. Much of my day-to-day practice involves reviewing antimicrobial choices, dosing, administration, renal function, therapeutic monitoring, and the practical challenges that influence how treatment is delivered. My path into this role began in hospital pharmacy operations, and that journey has shaped how I understand the pharmacist’s contribution to patient care.
There was a time when I thought my job ended when the medicine reached the patient.
Like many hospital pharmacists, I started my career focused on getting the medication process right: the prescription, the product, the dose, the route, the timing, and a safe supply to the ward. That work matters, and I still respect it. But over time I kept noticing that an antibiotic could be dispensed perfectly and still leave the important clinical questions unanswered.
Was it the right antibiotic for the suspected infection? Were the dose and dosing interval appropriate for the patient’s renal function? Did the cultures support continuing it? Could the way it was given affect whether the patient reached the drug exposure we wanted?
Those questions slowly moved my career from hospital pharmacy operations to work as an infectious diseases pharmacist and, eventually, to antimicrobial stewardship. I did not leave hospital pharmacy behind. I started to look at it differently.
Learning to see the patient behind the prescription
My interest in clinical pharmacy grew out of those questions, but the move was harder than changing a job title. Clinical work needs a different kind of mental space.
After a long shift of operational responsibilities, walking onto a clinical round means changing gears completely. The focus is no longer only the medication order. It is the patient: diagnosis, severity of illness, cultures, laboratory results, renal and hepatic function, allergies, spectrum, dose, frequency, route, duration, interactions, monitoring, and response.
I began joining rounds with the teams caring for critically ill patients in the CCU, medical intensive care unit (MICU), surgical ICU (SICU), and pediatric ICU (PICU). In those units, an antimicrobial decision is rarely an isolated decision. It is one piece of a clinical picture that keeps moving.
That is when I understood that a pharmacist’s value is not limited to supplying the medicine. It can also lie in helping the team make sense of that medicine for the patient in front of them.
From staff pharmacist to infectious diseases pharmacist
In August 2023, I was designated Staff Pharmacist, Infectious Diseases. The role still carried heavy operational work, including inpatient and intravenous (IV) pharmacy duties, while I tried to take part meaningfully in clinical rounds.
That period was hard, and it taught me something I now say often: clinical practice cannot be treated as an extra task added to an already full operational workload.
In January 2024, I was redesignated as an Infectious Disease Pharmacist, which finally gave me the space to focus mainly on clinical work. Over the following months, my work focused on practical antimicrobial optimization with ID and critical care colleagues, building tools that could carry pharmacotherapy principles to the bedside.
One of the first was a prolonged infusion strategy for beta-lactams. The aim was never to turn every dose into a long infusion. Beta-lactams exhibit time-dependent bactericidal activity. In selected patients, particularly critically ill patients in whom pharmacokinetic and pharmacodynamic (PK/PD) targets are hard to reach, a prolonged infusion can increase the percentage of the dosing interval during which free (unbound) beta-lactam concentrations remain above the organism’s minimum inhibitory concentration (MIC) [1].
Turning PK/PD into a nursing workflow
Writing the protocol was the easy part. It sets infusion times for selected beta-lactams in critically ill patients. For example, when ceftazidime-avibactam plus aztreonam is indicated in adults with normal renal and hepatic function, Infectious Diseases Society of America (IDSA) guidance lists ceftazidime-avibactam 2.5 g IV every 8 hours and aztreonam 2 g IV every 8 hours, each infused over 3 hours.2
Making a 3-hour infusion actually happen on a busy ICU shift was the real work. We trained nursing staff on extended infusion administration. We asked postgraduate trainees to write the infusion duration on the order itself, so the instruction traveled with the prescription instead of sitting in a protocol file nobody opens mid-shift. The protocol was approved by our ICU head of department and ID consultant, and that backing, together with the support of our ICU consultants, mattered more than any document I wrote.
Our biggest barrier was equipment. Infusion pumps in our ICU are mostly reserved for inotropes and sedation, so a 3-hour antibiotic infusion had to run through a manual dial-flow regulator. Without a pump, bedside checks of flow and delivered volume became particularly important.
That shaped how we used the protocol. We applied it selectively, to the patients most likely to benefit: mechanically ventilated patients, immunocompromised patients, and those with suspected or confirmed multidrug-resistant (MDR) Gram-negative infections.
I spent time at the bedside with ICU nurses, explaining why infusion time matters and how prolonged infusion is used internationally. Then I checked whether it was actually happening. Every day I reviewed medication flow sheets and input charts against the order. For a meropenem 1 g dose prescribed in a total volume of 100 mL over 3 hours, for example, I checked that the documented hourly volumes accounted for the full infusion and were consistent with the ordered duration. Charted volumes were a practical check, but they could not confirm the exact infusion rate. Where possible, we encouraged use of a dedicated intravenous lumen to reduce interruptions by other medications.
More recently, we began recommending simultaneous administration of ceftazidime-avibactam and aztreonam through a Y-site over 3 hours when this combination was indicated [2]. A published study reported compatibility at the concentrations and under the conditions tested [3]. Concurrent exposure allows avibactam to inhibit co-produced serine beta-lactamases that can otherwise inactivate aztreonam. IDSA lists this combination as an alternative for infections caused by New Delhi metallo-beta-lactamase (NDM)-producing Enterobacterales when aztreonam-avibactam is unavailable [2]. In practice, concurrent administration also means one 3-hour infusion window rather than two.
It taught me that pharmacology only helps a patient once it fits into somebody’s shift.
When the right antibiotic was no longer enough
My clinical questions became more specific. An antibiotic can be appropriate in principle and still be inappropriate for a particular patient.
I started looking harder at dose, frequency, route, administration, duration, and monitoring. On rounds, that could mean asking whether a dose needed adjustment, whether broad coverage was still justified, whether new laboratory results changed the balance of risk and benefit, or whether a patient needed closer therapeutic monitoring.
Vancomycin monitoring, which our unit performs using trough levels, became part of that thinking. So did renal risk with other high-risk antimicrobials, including colistin and aminoglycosides.
Medication safety work beyond antibiotics taught me the same lesson. A standard operating procedure (SOP) for IV sodium bicarbonate administration, written after a phlebitis concern, and our root cause analysis and adverse drug reaction reviews all pointed to a common problem: gaps in knowledge, process, communication, documentation, or monitoring can affect how a medication is used.
Renal function became part of every antimicrobial conversation
Critically ill patients made one principle impossible to ignore: the dose on the prescription is only one part of the treatment.
Renal function can change quickly in the ICU. A dose that was reasonable this morning may need another look tomorrow, and intermittent hemodialysis and continuous renal replacement therapy (CRRT) add another layer.
Renal dose adjustment was an intervention I found myself making again and again on ICU rounds. At the request of our nephrology colleagues, I built an ICU renal dose adjustment chart, including hemodialysis and CRRT considerations, so teams could check it the moment renal function changed instead of waiting for me to raise it. It was never meant to replace clinical judgment or specialist advice. It was meant to make the right decision faster and more consistent.
Since 2023, the renal dose adjustment interventions I documented have fallen from about 10 a month to 2 to 4 a month. I read that number carefully. It may mean prescribers were adjusting doses before my review. But intervention counts also move with ICU census, the number of patients with renal impairment, and how consistently we document, so I share it as a process observation, not as proof of better patient outcomes.
It changed how I review antimicrobials. I no longer ask only, “Is this drug indicated?” I now ask, “Is this drug, at this dose, by this route, and at this frequency, right for this patient’s physiology today, and how will we know if it is still right tomorrow?”
The clinical pharmacist does more than review antibiotics
As my clinical role grew, so did the education and communication side of it.
I have learned that an intervention lands far better when it arrives as a clinical solution rather than a correction. On rounds my conversations are usually verbal. I review the patient, identify the issue, talk it through with the treating team, and record the intervention in our log. The aim is never to win an argument about an antibiotic. It is to help the team reach the safest, most evidence-based decision for that patient.
One discussion shows how this works in practice. On rounds with a pulmonologist, we reviewed how ceftazidime-avibactam and aztreonam should be administered, and I recommended prolonged infusion under our protocol, with the two drugs given together through a Y-site. I shared the supporting IDSA guidance and a published Y-site compatibility study, and he agreed and implemented the recommendation [2,3]. It was a small change made through a routine clinical discussion. The approved protocol and supporting evidence helped turn the recommendation into a practical bedside decision.
Clinical pharmacy is collaborative. The prescriber brings the diagnostic and clinical picture. Microbiology brings the organism and its susceptibilities. Nursing brings what is actually happening at the bedside. Pharmacy brings pharmacotherapy: dosing, administration, interactions, monitoring, and medication safety. The best decisions usually come from putting those views together.
Then antimicrobial stewardship became official
In 2026, antimicrobial stewardship was formally established in my hospital, and I was appointed AMS Secretary.
In one sense it was a new chapter. In another, it was a continuation of work that had been happening one patient at a time. The difference was that individual interventions now needed a system around them.
A stewardship program cannot depend on whether one pharmacist happens to notice a problem on rounds. It needs a way to identify problems, document interventions, track patterns, share findings, educate teams, and check whether a change is working. That matches the structure the Centers for Disease Control and Prevention (CDC) describes in its Core Elements of Hospital Antibiotic Stewardship Programs: leadership commitment, accountability, pharmacy expertise, action, tracking, reporting, and education [4]. The Core Elements should be adapted to each hospital’s needs, resources, and context.
For me, the shift was in the question. I was no longer asking only, “What should we do for this patient?” I was starting to ask, “What do we keep seeing, and what process would help the next patient too?”
Starting with one ward and building from there
When a formal stewardship system is new, it is tempting to try to change everything at once. We chose to be practical: understand the gaps, build a structured way to document, and begin with a focused pilot.
The MICU became our starting point for restricted antimicrobial surveillance in September 2026. In the first month, we reviewed 16 cases involving six restricted antimicrobials. Antimicrobial prescribing was judged appropriate in 12 cases (75%). The remaining four cases (25%) required renal dose adjustment, and the treating teams accepted and implemented all four recommendations.
One month, one unit, and 16 cases provide a process baseline, not proof of improved patient outcomes, and I treat the findings that way. But the pilot told us something useful: in those four cases, the issue was renal dosing rather than antibiotic selection.
Recording indication, antimicrobial, dose and frequency, route, appropriateness, rationale, and acceptance turned those bedside observations into structured stewardship data and gave us a practical foundation for ongoing surveillance.
Documentation changes the conversation. Without it, a pharmacist may remember that the same problem has happened several times. With it, the whole team can see the pattern. A pattern can lead to an intervention, and an intervention can lead to education, a protocol, a change in the prescribing process, or a new monitoring step. Then the cycle starts again: reassess, learn, improve.
From one intervention to a system
This is the part of my journey I find most meaningful.
Early in my career, the impact of my work sat with the individual medication order. Then it moved to the individual patient. Now, through antimicrobial stewardship, I am learning to think one level higher: how can individual clinical decisions generate learning for the whole hospital?
That does not mean every antibiotic needs to be restricted or every prescription challenged. Stewardship is not about building barriers between pharmacists and prescribers. It is about making antimicrobial decisions more deliberate.
Sometimes the intervention is de-escalation. Sometimes it is dose optimization, renal adjustment, monitoring, or a question about duration. Sometimes it is recognizing that a decision needs better diagnostic information. And sometimes the most valuable intervention does not change today’s prescription at all. It finds out why the same problem keeps happening and fixes the process around it.
I am still learning
Moving into infectious diseases and stewardship has made me more comfortable with not knowing everything.
Antimicrobial therapy sits where microbiology, pharmacology, physiology, diagnostics, and clinical judgment meet. Each year in this work has shown me a new gap in what I know, and I no longer treat that as a weakness.
That is especially true in critical care, where physiology moves quickly and the evidence does not answer every bedside question. So my job on rounds is not to arrive with every answer. It is to ask better questions, use the evidence well, recognize when specialist input is needed, communicate clearly, and keep the patient at the center of the decision. That mindset has changed my practice more than any single protocol or guideline.
Five lessons for pharmacists making the same move
If you are an operational pharmacist thinking about infectious diseases or stewardship work, these are the lessons I wish someone had handed me earlier.
1. Protect clinical time. Clinical work squeezed between dispensing duties is difficult to sustain. Ask for a role or schedule that makes room for it.
2. Bring solutions, not corrections. A recommendation framed around the patient is easier for the team to act on than one framed around an error.
3. Put the instruction where the work happens. Writing the infusion duration on the order, then checking the flow sheets every day, is what turned our prolonged infusion protocol into practice.
4. Write everything down. One remembered problem is an anecdote. Ten documented ones are a pattern your committee can act on.
5. Start with one unit. A focused pilot, like our MICU documentation, can show what needs to be improved before expanding to other units.
The question that changed my career
Looking back, my career can be described through job titles:
Staff Pharmacist. Staff Pharmacist, Infectious Diseases. Infectious Disease Pharmacist. AMS Secretary.
But the titles are not really what changed. The questions changed.
At first: “What medication should I dispense?” Then: “Is this antibiotic appropriate?” Then: “How can we optimize this antibiotic for this patient?” And now: “How can we build a system that helps the whole team make better antimicrobial decisions?”
That progression took me from the pharmacy counter to the clinical ward, and from individual interventions to antimicrobial stewardship.
I once thought the pharmacist’s job ended when the medicine reached the patient. Now I see the opposite. That is where the pharmacist’s clinical responsibility can truly begin.
For me, antimicrobial stewardship means making each antimicrobial decision more deliberate, evidence-based, and specific to the patient, and helping build a clinical culture in which that becomes part of everyday practice.
Author bio

Maira Baseer, Pharm.D., is an infectious diseases pharmacist and AMS secretary at a tertiary care hospital in Pakistan, with more than seven years of experience in hospital and clinical pharmacy. Her clinical practice includes antimicrobial optimization, critical care rounds, renal dose adjustment, medication safety, therapeutic monitoring, clinician and nursing education, and building practical antimicrobial stewardship processes. Her interests include infectious diseases pharmacotherapy, PK/PD-informed antibiotic optimization, and the growing role of pharmacists in settings with varying resources.
Disclosure
The author declares no conflicts of interest related to this article.
References
- Hong LT, Downes KJ, FakhriRavari A, et al. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics. Pharmacotherapy. 2023;43(8):740-777. doi:10.1002/phar.2842
- Tamma PD, Bonomo RA, Heil EL, Justo JA, Satlin MJ, Mathers AJ. Infectious Diseases Society of America 2026 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Infectious Diseases Society of America; 2026 (Current as of March 1, 2026). Available at: https://www.idsociety.org/practice-guideline/amr-guidance/. Accessed October 2026.
- O’Donnell JN, Xu A, Lodise TP. Intravenous compatibility of ceftazidime-avibactam and aztreonam using simulated and actual Y-site administration. Clin Ther. 2020;42(8):1580-1586.e2. doi:10.1016/j.clinthera.2020.06.005
- Centers for Disease Control and Prevention. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. Available at: https://www.cdc.gov/antibiotic-use/hcp/core-elements/hospital.html. Accessed October 2026.
RECOMMENDED TO YOU


